Skip to main content
. Author manuscript; available in PMC: 2010 Mar 4.
Published in final edited form as: J Nucl Med. 2008 Mar;49(3):341–344. doi: 10.2967/jnumed.107.045112

FIGURE 2.

FIGURE 2

Serial studies of same TRAMP mouse demonstrate ability to follow disease progression in this transgenic model of prostate cancer. All 13C MRSI data were acquired in 14 s using 3D double spin-echo flyback echoplanar spectroscopic imaging sequence (20) with TR of 215 ms, variable spin echo, and spatial resolution of 0.135 cm3. This new technique is seen to be feasible for following disease progression and monitoring therapeutic response in preclinical cancer models.